Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289054 · ClinicalTrials.gov registry record
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4
- Enrollment target
NCT01289054 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT01289054 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.
Interventions
- DRUG Gleevec
- DRUG Tasigna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289054
The ClinicalTrials.gov registry entry for NCT01289054 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gleevec is the first listed.
NCT01289054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289054 about?
NCT01289054 is a clinical study titled "A Global Imatinib and Nilotinib Pregnancy Exposure Registry". This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.
What is the current status of trial NCT01289054?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01289054?
The interventions under investigation include: Gleevec (DRUG), Tasigna (DRUG).
Who is sponsoring clinical trial NCT01289054?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.